Medtronic beat second-quarter profit and revenue estimates and raised its annual earnings forecast on Tuesday, banking on strong sales in its surgical and diabetes units, sending shares of the company up about 2% in premarket trading. Medical device makers are seeing higher demand for their products due to a steady recovery in surgical procedures that were deferred during the pandemic, especially by older adults, as well as easing staff shortages at hospitals. Medtronic, which makes pacemakers, catheters and tools used in heart and gastrointestinal surgeries, joins Abbott Laboratories and Boston Scientific, which have also benefited from soaring demand for non-urgent surgeries.